Mátyás Keltai

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of c...

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Initial Invasive or Conservative Strategy for Stable Coronary Disease

Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative...